课题基金 / 基金详情

项目摘要

项目成果

MICHAEL D GUNN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Chlorine gas (CI2) is a readily available chemical warfare agent that causes a dose-dependent toxicity to pulmonary and other mucosal tissues. The major toxicity of CI2 exposure is oxidative damage of lung tissues that is thought to be due to the direct effects of CI2 reaction products combined with inflammatory mediators released by lung-infiltrating leukocytes. This proposed mechanism has not been clearly demonstrated but raises the possibility that inhibition of pulmonary inflammation following CI2 exposure will reduce subsequent morbidity and mortality. Our laboratory has identified the cells and the cell migration events that lead to immune-mediated lung damage, morbidity, and mortality during viral and bacterial infections. Our preliminary studies demonstrate that a similar pattern of inflammation occurs after chlorine exposure. These findings suggest that chlorine-induced lung injury could be substantially lessened using a specific chemokine receptor antagonist. Importantly, a pharmacologic antagonist for the chemokine receptor we have identified has already been developed and proven to be safe and effective in early clinical trials for other indications. This raises the possibility that a drug already exists that would reduce the morbidity and mortality of chlorine exposure in humans. In a series of murine studies, we will determine the extent to which specific pulmonary inflammatory cell types contribute to chlorine-induced lung injury and the consequent epithelial damage, bronchial reactivity, morbidity, and mortality. We will then examine the ability of the chemokine receptor antagonist to reduce these toxicities. These studies will provide a basis for determining if trials of chemokine receptor antagonists should be considered in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of point-of-care testing for Lassa and other hemorrhagic fever arenaviruses
  • 批准号:
    10656548
  • 项目类别:
  • 资助金额:
    $39.7万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL D GUNN
  • 依托单位:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
  • 批准号:
    10092930
  • 项目类别:
  • 资助金额:
    $19.73万
  • 财政年份:
    2020
  • 负责人:
    MICHAEL D GUNN
  • 依托单位:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
  • 批准号:
    9896170
  • 项目类别:
  • 资助金额:
    $23.77万
  • 财政年份:
    2020
  • 负责人:
    MICHAEL D GUNN
  • 依托单位:
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma
  • 批准号:
    10246886
  • 项目类别:
  • 资助金额:
    $56.58万
  • 财政年份:
    2018
  • 负责人:
    MICHAEL D GUNN
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: